PE20220143A1 - Agonistas de glp-1r y usos de los mismos - Google Patents
Agonistas de glp-1r y usos de los mismosInfo
- Publication number
- PE20220143A1 PE20220143A1 PE2021001694A PE2021001694A PE20220143A1 PE 20220143 A1 PE20220143 A1 PE 20220143A1 PE 2021001694 A PE2021001694 A PE 2021001694A PE 2021001694 A PE2021001694 A PE 2021001694A PE 20220143 A1 PE20220143 A1 PE 20220143A1
- Authority
- PE
- Peru
- Prior art keywords
- membered
- saturated
- ring
- compounds
- alkoxy
- Prior art date
Links
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- BGCPLWWYPZAURQ-UHFFFAOYSA-N 5-[[5-chloro-2-(2,2,6,6-tetramethylmorpholin-4-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one Chemical group ClC=1C(=NC(=NC=1)N1CC(OC(C1)(C)C)(C)C)NC1=CC2=C(N(C(N2CCC(C)(C)O)=O)C)C=C1 BGCPLWWYPZAURQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 101150063022 CHRD gene Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101100274355 Danio rerio chd gene Proteins 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripcion proporciona compuestos de Formula (I) o una sal farmaceuticamente aceptable del mismo, en donde: el enlace en el anillo C indica un enlace simple o un enlace doble; X1, X2, X3, X4 y X5 se seleccionan cada uno independientemente de N y CH; W se selecciona de O, S, CR5R6 y NR5'; el anillo B es heteroarilo de 6 miembros, heterociclilo monociclico de 6 miembros o fenilo, en donde Y1 se selecciona de N, NH, CH y CH2; el anillo C es ciclohexilo, fenilo o piridilo; L es CHRd, O, S o NR5'; el anillo D es heteroarilo biciclico; EE es -COOH o un sustituto del grupo carboxilico; cada Ra y Rb se seleccionan independientemente de hidrogeno, deuterio, halogeno, -CN, alquilo C1-C6, alcoxi C1-C6, NR5'R6', arilo de 6-10 miembros, heteroarilo de 5-8 miembros, cicloalquilo de 3-8 miembros saturado o parcialmente saturado y heterociclilo de 3-8 miembros saturado o parcialmente saturado, en donde el alquilo C1-C6 o alcoxi C1-C6; cada Rc y Rd se seleccionan independientemente de hidrogeno, deuterio, halogeno, -CN, alquilo C1-C6, alcoxi C1-C6, NR5'R6', arilo de 6-10 miembros, heteroarilo de 5-8 miembros, cicloalquilo de 3-8 miembros saturado o parcialmente saturado y heterociclilo de 3-8 miembros saturado o parcialmente saturado; cada R1, R2, R3 y R4 se selecciona o sustituye segun la invencion. Son compuestos preferidos los seleccionados de los compuestos 74-102 y 246-334 o unal sal, estereoisomero, solvato o hidrato farmaceuticamente aceptable del mismo. Tambien se refiere a una composicion farmaceutica y metodos que comprenden el compuesto de la invencion. Dichos compuestos son agonistas del receptor de GLP-1 (GLP-1R) utiles en el tratamiento de diabetes mellitus tipo 2 (T2DM), prediabetes, obesidad, enfermedad del higado graso no alcoholico, esteatohepatitis no alcoholica y enfermedad cardiovascular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019082381 | 2019-04-12 | ||
| PCT/CN2020/084203 WO2020207474A1 (en) | 2019-04-12 | 2020-04-10 | Glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220143A1 true PE20220143A1 (es) | 2022-01-27 |
Family
ID=72750961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001694A PE20220143A1 (es) | 2019-04-12 | 2020-04-10 | Agonistas de glp-1r y usos de los mismos |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20230278991A1 (es) |
| EP (1) | EP3953344A4 (es) |
| JP (2) | JP7635145B2 (es) |
| KR (1) | KR20210152513A (es) |
| CN (1) | CN113853371B (es) |
| AU (1) | AU2020256647B2 (es) |
| BR (1) | BR112021020335A2 (es) |
| CA (1) | CA3136375A1 (es) |
| CL (1) | CL2021002649A1 (es) |
| CO (1) | CO2021015060A2 (es) |
| CR (1) | CR20210562A (es) |
| CU (1) | CU20210083A7 (es) |
| DO (1) | DOP2021000208A (es) |
| EA (1) | EA202192684A1 (es) |
| IL (1) | IL287128A (es) |
| MA (1) | MA55627A (es) |
| MX (1) | MX2021012492A (es) |
| PE (1) | PE20220143A1 (es) |
| PH (1) | PH12021552557A1 (es) |
| SA (1) | SA521430550B1 (es) |
| SG (1) | SG11202110825WA (es) |
| WO (1) | WO2020207474A1 (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019382642B2 (en) | 2018-11-22 | 2025-05-29 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022007627A2 (pt) * | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| WO2021112538A1 (en) | 2019-12-02 | 2021-06-10 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| CN115335374B (zh) * | 2020-01-29 | 2025-05-27 | 吉利德科学公司 | Glp-1r调节化合物 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115279750B (zh) * | 2020-03-18 | 2024-06-21 | 株式会社Lg化学 | Glp-1受体激动剂、包含该激动剂的药物组合物及其制备方法 |
| MY207021A (en) * | 2020-03-18 | 2025-01-24 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN113831337B (zh) * | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| CR20230066A (es) | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US20230382899A1 (en) * | 2020-10-14 | 2023-11-30 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| US20240246959A1 (en) * | 2020-11-27 | 2024-07-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| MX2023007569A (es) * | 2020-12-25 | 2023-09-21 | Xizang Haisco Pharmaceutical Co Ltd | Derivado de anillo de cinco miembros y uso medico de este. |
| CN114805336A (zh) * | 2021-01-20 | 2022-07-29 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
| US20230089073A1 (en) | 2021-01-28 | 2023-03-23 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| CN117222631A (zh) * | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| WO2022216094A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| KR102824619B1 (ko) * | 2021-04-08 | 2025-06-25 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| CA3215916A1 (en) * | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| CN117279905A (zh) * | 2021-04-21 | 2023-12-22 | 吉利德科学公司 | 羧基-苯并咪唑glp-1r调节化合物 |
| AU2022263410B2 (en) * | 2021-04-21 | 2024-08-01 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| FI4271674T3 (fi) * | 2021-04-21 | 2025-04-23 | Gilead Sciences Inc | Glp-1r:ää moduloivia karboksibentsimidatsoliyhdisteitä |
| JP2024516291A (ja) * | 2021-05-03 | 2024-04-12 | カーモット セラピューティクス インコーポレイテッド | ベンゾイミダゾイルｇｌｐ－１受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
| CN117355517A (zh) * | 2021-05-20 | 2024-01-05 | 伊莱利利公司 | 大环胰高血糖素样肽1受体激动剂 |
| TWI843104B (zh) * | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN117098758A (zh) * | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| CN117715906A (zh) * | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| WO2023011539A1 (zh) * | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
| CN120518588A (zh) * | 2021-08-30 | 2025-08-22 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| CN118948849A (zh) | 2021-09-08 | 2024-11-15 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| HRP20251161T1 (hr) | 2021-09-27 | 2025-11-21 | Terns Pharmaceuticals, Inc. | Benzimidazol karboksilne kisele kao agonisti glp-1r |
| US20240417393A1 (en) | 2021-10-05 | 2024-12-19 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| TW202334129A (zh) | 2021-10-25 | 2023-09-01 | 美商拓臻製藥公司 | 作為ｇｌｐ—１ｒ促效劑的化合物 |
| CA3239813A1 (en) * | 2021-12-03 | 2023-06-08 | Lu Gan | Crystal forms of thienoimidazole compound and preparation method thereof |
| JPWO2023106310A1 (es) * | 2021-12-07 | 2023-06-15 | ||
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| CN118613476A (zh) * | 2022-01-10 | 2024-09-06 | 西藏海思科制药有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
| WO2023164050A1 (en) | 2022-02-23 | 2023-08-31 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CA3253533A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co Ltd | GLP-1R MODULATOR COMPOUNDS |
| US20230271949A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| EP4491625A1 (en) | 2022-03-08 | 2025-01-15 | Guangzhou Unirise Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| KR20240135652A (ko) * | 2022-05-20 | 2024-09-11 | 쳉두 띠아오 지우홍 파마수티칼 팩토리 | 벤즈이미다졸 또는 아자벤즈이미다졸 화합물, 이의 제조 방법 및 그의 용도 |
| TW202408504A (zh) * | 2022-06-23 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| WO2024041609A1 (zh) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| KR20250047817A (ko) * | 2022-09-06 | 2025-04-04 | 민드랭크 테라퓨틱스 (수저우) 뉴 드러그 리서치 앤 디벨롭먼트 컴퍼니, 리미티드 | Glp-1r 작용제 화합물의 결정다형체 및 이의 제조 방법과 용도 |
| JPWO2024063143A1 (es) | 2022-09-22 | 2024-03-28 | ||
| KR20250105662A (ko) | 2022-11-11 | 2025-07-08 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| EP4619098A1 (en) | 2022-11-16 | 2025-09-24 | Eli Lilly and Company | Glucagon-like peptide 1 receptor agonists |
| CN118184637A (zh) * | 2022-12-13 | 2024-06-14 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的新晶型和制备方法及其药物组合物和用途 |
| CN116082321A (zh) * | 2022-12-23 | 2023-05-09 | 华中药业股份有限公司 | 一种咪唑并芳杂基类衍生物、药物组合物及其应用 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| KR20250125490A (ko) * | 2024-02-14 | 2025-08-22 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO2009111700A2 (en) | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| SG185515A1 (en) * | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| RU2634896C2 (ru) * | 2011-12-12 | 2017-11-08 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
| AU2017374860B2 (en) * | 2016-12-16 | 2021-09-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| PT3806855T (pt) * | 2018-06-15 | 2023-05-03 | Pfizer | Agonistas dos receptores de glp-1 e suas utilizações |
| AU2019382642B2 (en) * | 2018-11-22 | 2025-05-29 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| BR112022007627A2 (pt) * | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| WO2021112538A1 (en) * | 2019-12-02 | 2021-06-10 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
-
2020
- 2020-04-10 CU CU2021000083A patent/CU20210083A7/es unknown
- 2020-04-10 JP JP2021560022A patent/JP7635145B2/ja active Active
- 2020-04-10 EA EA202192684A patent/EA202192684A1/ru unknown
- 2020-04-10 KR KR1020217036543A patent/KR20210152513A/ko active Pending
- 2020-04-10 SG SG11202110825WA patent/SG11202110825WA/en unknown
- 2020-04-10 PE PE2021001694A patent/PE20220143A1/es unknown
- 2020-04-10 MX MX2021012492A patent/MX2021012492A/es unknown
- 2020-04-10 WO PCT/CN2020/084203 patent/WO2020207474A1/en not_active Ceased
- 2020-04-10 BR BR112021020335A patent/BR112021020335A2/pt unknown
- 2020-04-10 CN CN202080028229.XA patent/CN113853371B/zh active Active
- 2020-04-10 CA CA3136375A patent/CA3136375A1/en active Pending
- 2020-04-10 CR CR20210562A patent/CR20210562A/es unknown
- 2020-04-10 EP EP20788321.6A patent/EP3953344A4/en active Pending
- 2020-04-10 AU AU2020256647A patent/AU2020256647B2/en active Active
- 2020-04-10 MA MA055627A patent/MA55627A/fr unknown
- 2020-04-10 PH PH1/2021/552557A patent/PH12021552557A1/en unknown
-
2021
- 2021-10-08 CL CL2021002649A patent/CL2021002649A1/es unknown
- 2021-10-10 IL IL287128A patent/IL287128A/en unknown
- 2021-10-11 SA SA521430550A patent/SA521430550B1/ar unknown
- 2021-10-11 DO DO2021000208A patent/DOP2021000208A/es unknown
- 2021-11-08 CO CONC2021/0015060A patent/CO2021015060A2/es unknown
-
2023
- 2023-02-24 US US18/113,859 patent/US20230278991A1/en not_active Abandoned
-
2024
- 2024-09-10 US US18/830,194 patent/US20250042883A1/en active Pending
-
2025
- 2025-02-10 JP JP2025019723A patent/JP2025072577A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250042883A1 (en) | 2025-02-06 |
| JP7635145B2 (ja) | 2025-02-25 |
| EA202192684A1 (ru) | 2021-12-28 |
| CO2021015060A2 (es) | 2021-11-19 |
| AU2020256647A1 (en) | 2021-11-18 |
| PH12021552557A1 (en) | 2022-07-04 |
| AU2020256647B2 (en) | 2025-07-31 |
| CA3136375A1 (en) | 2020-10-15 |
| CR20210562A (es) | 2022-02-18 |
| IL287128A (en) | 2021-12-01 |
| SG11202110825WA (en) | 2021-10-28 |
| JP2025072577A (ja) | 2025-05-09 |
| WO2020207474A1 (en) | 2020-10-15 |
| CN113853371B (zh) | 2024-05-03 |
| EP3953344A1 (en) | 2022-02-16 |
| US20230278991A1 (en) | 2023-09-07 |
| CU20210083A7 (es) | 2022-05-11 |
| JP2022527607A (ja) | 2022-06-02 |
| KR20210152513A (ko) | 2021-12-15 |
| EP3953344A4 (en) | 2023-08-09 |
| DOP2021000208A (es) | 2021-11-21 |
| MX2021012492A (es) | 2021-11-12 |
| SA521430550B1 (ar) | 2025-04-14 |
| MA55627A (fr) | 2022-02-16 |
| CL2021002649A1 (es) | 2022-05-06 |
| CN113853371A (zh) | 2021-12-28 |
| BR112021020335A2 (pt) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| PE20211871A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR076551A1 (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR056548A1 (es) | Derivados de sulfonamidas, composiciones farmaceuticas y sus usos | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| ES2929140T3 (es) | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat | |
| AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
| CL2018000036A1 (es) | Derivados etinilo | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| PE20090218A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR076219A1 (es) | Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR053548A1 (es) | Derivados de oxiindol | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
| AR061656A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y procesos para la preparacion de la composicion y del compuesto |